Desktop 3D printer manufacturer UltiMaker and Singaporean MedTech startup Bioactivx have signed a memorandum of understanding (MoU) to jointly develop a deployable, on-demand 3D printing solution for regenerative wound care.
The announcement coincides with two milestones Bioactivx reached. The more significant of the two is Health Sciences Authority (HSA) approval for Bioactivx’s flagship product, the Bioactiv Matrix, a fully synthetic, animal-free artificial skin substitute designed to treat severe burns, cuts, and abrasions.
Singapore’s HSA sits at World Health Organization (WHO) Maturity Level 4 for medical device regulation, indicating extremely high standards for medical device approvals, and Bioactivx has ongoing regulatory submissions in the United States, the European Union, Australia, and across the rest of ASEAN.
“Bioactivx’s certification and regulatory approval is a powerful proof point for the medical 3D printing industry,” said Mr. Michiel Alting von Geusau, CEO of UltiMaker “It demonstrates that with the right process and quality controls, 3D printing on UltiMaker platforms can meet the exacting standards required for certified, end-use medical devices – not just prototypes.”
Developing On-Demand Medical Manufacturing
The Bioactiv Matrix is manufactured through a digital production process that Bioactivx built entirely around UltiMaker hardware. The company compounds a proprietary active-ingredient filament in-house, then runs the final product through a fleet of UltiMaker 3D printers inside a certified cleanroom facility, which it also opened alongside the MoU announcement.
That end-to-end process is what earned Bioactivx both ISO 13485 certification and HSA approval specifically for end-use medical manufacturing, a more demanding bar than prototyping or component production.
Under the MoU, the two companies will work over the coming months to refine a 3D printing configuration that can be deployed closer to where treatment is needed, instead of depending on centralized manufacturing and cold-chain distribution.
The stated aim is to shorten the time between injury and treatment within what Bioactivx describes as the critical window following a wound, though no specific deployment timeline or unit targets were disclosed.
A validated on-demand 3D printing setup, if it clears regulatory requirements in each target market, could allow a product like the Bioactiv Matrix to be manufactured at or near the point of use.
3D Printing Finds Clinical Wound Care Applications
3D printing’s application to wound care has been producing results at the clinical level. At the University of Toledo Medical Center, physicians used the Aplicor 3D bioprinter, developed by Tides Medical, to 3D print patient-specific grafts derived from a small sample of a patient’s own fat tissue.
The graft is shaped to fit the exact dimensions of the wound, and at least one patient with a persistent chronic lesion reported visible wound closure within two weeks of the procedure.
In a parallel development, Swiss biotech company Cutiss reported positive interim results in 2025 from two phase II clinical trials of denovoSkin, a bilayer skin substitute, tested in children and adults recovering from burns or reconstructive surgery. At the time of reporting, the company announced a European phase III trial in the pipeline, and has already extended access to a limited number of patients in the US and Europe under compassionate-use exemptions.
These developments illustrate 3D printing and engineered skin technologies moving into clinical treatment and clinical development, while production time, scalability, and regulatory requirements remain constraints. The Bioactivx-UltiMaker MoU addresses a different part of this challenge by focusing on how an already regulated wound-care product could eventually be manufactured closer to the point of treatment.
Further validation and regulatory clearance in each target market will determine how viable that model proves beyond Singapore.
Register now for AMA: Software 2026. Join 3D Printing Industry on 22 October for expert presentations, panel discussions and live audience Q&A exploring the software shaping additive manufacturing. Register here.
To stay up to date with the latest 3D printing news, don’t forget to subscribe to the 3D Printing Industry newsletter or follow us on Twitter, or like our page on Facebook.
While you’re here, why not subscribe to our Youtube channel? Featuring discussion, debriefs, video shorts, and webinar replays.
Featured image shows from left to right: UltiMaker CEO, Michiel Alting von Geusau, Member of Parliament and Guest of Honor Ms Tin Pei Ling, and BioactivX CEO, Dr Peili Teo, at the MoU signing. Photo via UltiMaker.
Facts Only
* UltiMaker and Bioactivx signed a memorandum of understanding.
* Bioactivx developed the Bioactiv Matrix, a synthetic, animal-free artificial skin substitute.
* Singapore's Health Sciences Authority (HSA) approved the Bioactiv Matrix.
* Bioactivx holds ISO 13485 certification for end-use medical manufacturing.
* Bioactivx opened a certified cleanroom facility.
* The Bioactiv Matrix is produced using a proprietary active-ingredient filament and UltiMaker 3D printers.
* Bioactivx has pending regulatory submissions in the United States, European Union, Australia, and ASEAN.
* Tides Medical developed the Aplicor 3D bioprinter for patient-specific fat-tissue grafts.
* Cutiss reported interim results from phase II clinical trials of denovoSkin in 2025.
* Cutiss is planning a phase III trial in Europe.
Executive Summary
UltiMaker and Bioactivx have entered a memorandum of understanding to develop a deployable, on-demand 3D printing system for regenerative wound care. This collaboration follows the Health Sciences Authority (HSA) approval of the Bioactiv Matrix, a synthetic, animal-free artificial skin substitute for treating severe burns and abrasions. Bioactivx utilizes a proprietary filament and a fleet of UltiMaker printers within a certified cleanroom to achieve ISO 13485 certification and medical manufacturing approval.
The goal of the partnership is to shift production from centralized facilities and cold-chain distribution to a model where treatment is manufactured closer to the point of injury, reducing the time between trauma and intervention. While other clinical efforts, such as those by Tides Medical and Cutiss, utilize bioprinting for patient-specific grafts and bilayer skin substitutes, the Bioactivx-UltiMaker initiative focuses specifically on the logistics of regulated manufacturing deployment. Success depends on clearing regulatory hurdles in target markets across the US, EU, Australia, and ASEAN.
Full Take
The strongest version of this narrative is that 3D printing is transitioning from a prototyping tool to a certified medical manufacturing platform, potentially decentralizing the supply chain for critical wound care. By moving production closer to the patient, the industry could bypass the systemic failures and costs of cold-chain logistics.
The narrative relies heavily on the "Authority Game," using the HSA’s WHO Maturity Level 4 status to validate the technology's readiness. While the regulatory approval is a factual milestone, the projection that this proves the viability of "on-demand" deployment is a leap. The transition from a certified cleanroom facility to a "deployable" configuration introduces significant variables regarding quality control and sterility that are not addressed. The piece frames the problem as one of distance and time, positioning UltiMaker hardware as the bridge to the solution.
Patterns detected: ARC-0031 Authority Game
This narrative is driven by the paradigm of "distributed manufacturing," which assumes that the primary barrier to care is logistics rather than biology or cost. If successful, this shifts agency toward point-of-care providers but creates new dependencies on proprietary hardware and filaments. The second-order consequence is a potential shift in regulatory burden from the manufacturer to the site of deployment.
Bridge Questions:
1. How does the risk profile change when a medical device is printed at the point of use versus a centralized, certified facility?
2. What are the economic implications for healthcare providers who must maintain specialized hardware to receive this treatment?
Counterstrike Scan: A coordinated campaign would use the "miracle tech" trope and regulatory prestige to inflate stock value or secure government grants before a viable deployable prototype exists. The current content is standard industry reporting and does not match this attack pattern.